ZYNERBA PHARMACEUTICALS INC's ticker is ZYNE and the CUSIP is 98986X109. A total of 64 filers reported holding ZYNERBA PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 2.60 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $96,000 | -36.4% | 131,036 | -1.0% | 0.01% | -43.5% |
| Q2 2022 | $151,000 | -51.1% | 132,405 | -12.3% | 0.02% | -43.9% |
| Q1 2022 | $309,000 | -60.4% | 150,914 | -44.3% | 0.04% | -58.2% |
| Q4 2021 | $780,000 | +445.5% | 270,772 | +701.4% | 0.10% | +553.3% |
| Q3 2021 | $143,000 | +6.7% | 33,788 | +52.8% | 0.02% | -6.2% |
| Q4 2019 | $134,000 | -24.3% | 22,106 | +1.9% | 0.02% | +60.0% |
| Q3 2018 | $177,000 | -63.6% | 21,700 | -44.1% | 0.01% | -66.7% |
| Q4 2017 | $486,000 | +162.7% | 38,800 | +256.0% | 0.03% | +150.0% |
| Q2 2017 | $185,000 | -70.1% | 10,900 | -64.6% | 0.01% | -63.6% |
| Q1 2017 | $619,000 | +189.3% | 30,800 | +124.8% | 0.03% | +153.8% |
| Q4 2016 | $214,000 | – | 13,700 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 507,191 | $5,107,000 | 0.50% |
| Cormorant Asset Management, LP | 356,600 | $3,591,000 | 0.43% |
| Perceptive Advisors | 558,446 | $5,623,000 | 0.42% |
| NEXTHERA CAPITAL LP | 15,000 | $151,000 | 0.21% |
| EMERALD ADVISERS, LLC | 237,070 | $2,387,000 | 0.11% |
| AUXIER ASSET MANAGEMENT | 17,857 | $180,000 | 0.04% |
| FEDERATED HERMES, INC. | 450,000 | $4,532,000 | 0.01% |
| Nationwide Fund Advisors | 49,473 | $498,000 | 0.00% |
| Catalyst Capital Advisors LLC | 348 | $4,000 | 0.00% |
| DEUTSCHE BANK AG\ | 859 | $8,000 | 0.00% |